These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30219449)

  • 1. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
    Zuzak TJ; Wasmuth A; Bernitzki S; Schwermer M; Längler A
    Complement Ther Med; 2018 Oct; 40():198-202. PubMed ID: 30219449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
    Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
    Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
    Pelzer F; Tröger W; Nat DR
    J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
    Thronicke A; Steele ML; Grah C; Matthes B; Schad F
    BMC Complement Altern Med; 2017 Dec; 17(1):534. PubMed ID: 29237435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
    Melzer J; Iten F; Hostanska K; Saller R
    Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
    Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
    BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings.
    Sunjic SB; Gasparovic AC; Vukovic T; Weiss T; Weiss ES; Soldo I; Djakovic N; Zarkovic T; Zarkovic N
    Coll Antropol; 2015 Sep; 39(3):701-8. PubMed ID: 26898069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
    Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
    Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
    Bar-Sela G; Gershony A; Haim N
    Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract.
    Eisenbraun J; Scheer R; Kröz M; Schad F; Huber R
    Phytomedicine; 2011 Jan; 18(2-3):151-7. PubMed ID: 20724129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
    Schad F; Axtner J; Kröz M; Matthes H; Steele ML
    Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mistletoe in the treatment of cancer patients].
    Rostock M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy.
    Menke K; Schwermer M; Felenda J; Beckmann C; Stintzing F; Schramm A; Zuzak TJ
    Complement Ther Med; 2018 Oct; 40():158-164. PubMed ID: 30219442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
    Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
    Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series.
    von Schoen-Angerer T; Wilkens J; Kienle GS; Kiene H; Vagedes J
    Perm J; 2015; 19(4):76-83. PubMed ID: 26517439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.
    Oei SL; Thronicke A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2019; 18():1534735419832367. PubMed ID: 30808274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mistletoe: for cancer or just for Christmas?
    de Giorgio A; Stebbing J
    Lancet Oncol; 2013 Dec; 14(13):1264-5. PubMed ID: 24275128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.